Physicians

Department / Division
Medicine / Medicine-Rheumatology and Immunology

Address
DUMC 3440
Durham, NC 27710

Appointment Telephone
919-613-2243

Office Telephone
919-684-2965

Fax Telephone
919-684-8358

Training

• MD, Tufts University School of Medicine (Massachusetts), 1978

Residency

• Medicine, Duke University Medical Center, 1978-1981
• Rheumatology, Duke University Medical Center, 1981-1983

Clinical Interests
Systemic vasculitis, Wegener's granulomatosis, temporal arteritis, Takayasu arteritis, systemic lupus erythematosus, erosive osteoarthritis, antiphospholipid antibody syndrome, women with rheumatic disease, Behcet's syndrome, retroperitoneal fibrosis

Research Interests
My clinical research interests include systemic vasculitis (Wegener's granulomatosis, microscopic polyangiitis, giant cell arteritis, Takayasu arteritis) and multi-disciplinary efforts in the areas of systemic lupus erythematosus and anti-phospholipid syndrome. Dr. E. William St. Clair and I represented Duke in both the RAVE trial, a multi-center, double-blind, controlled trial comparing rituximab with cyclophosphamide in patients with ANCA-associated vasculitis and previously the Wegener's granulomatosis etanercept trial (WGET), a multi-center effort to assess the addition of etanercept to traditional therapy in limited and severe forms of this type of vasculitis.

My area of clinical expertise is in the care of patients with all types of vasculitis, particularly Granulomatosis with Polyangiitis (formerly called Wegener's granulomatosis), Micropscopic Polyangiitis, other ANCA-associated vasculitides, giant cell arteritis, and Takayasu's arteritis. I also care for patients with systemic lupus erythematosus, anti-phospholipid syndrome, and women's health-related rheumatologic diseases. In addition I see all patients and educate trainees about all types of rheumatologic and arthritis conditions. Key words: vasculitis, systemic vasculitis, Wegener's granulomatosis, giant cell (temporal) arteritis, Takayasu arteritis, anti-phospholipid antibody syndrome.

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Genentech, Inc (Roche Holding)

Representative Publications
Stone, JH; Merkel, PA; Spiera, R; Seo, P; Langford, CA; Hoffman, GS; Kallenberg, CG; St Clair, EW; Turkiewicz, A; Tchao, NK; Webber, L; Ding, L; Sejismundo, LP; Mieras, K; Weitzenkamp, D; Ikle, D; Seyfert-Margolis, V; Mueller, M; Brunetta, P; Allen, NB; Fervenza, FC; Geetha, D; Keogh, KA; Kissin, EY; Monach, PA; Peikert, T; Stegeman, C; Ytterberg, SR; Specks, U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New England Journal of Medicine. 2010;363:221-232. (2010) Abstract

Wung, PK; Holbrook, JT; Hoffman, GS; Tibbs, AK; Specks, U; Min, YI; Merkel, PA; Spiera, R; Davis, JC; St Clair, EW; McCune, J; Ytterberg, SR; Allen, NB; Stone, JH; WGET Research Group. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. American Journal of Medicine. 2005;118:1416. (2005) Abstract

Hansen, KE; Moore, KD; Ortel, TL; Allen, NB. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis and Rheumatism. 1999;42:2250-2252. (1999) Abstract